- Home
- MRNA vs QGEN Comparison
MRNA vs QGEN Comparison
Compare MRNA & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- QGEN
- Stock Information
- Founded
- MRNA 2010
- QGEN 1986
- Country
- MRNA United States
- QGEN Netherlands
- Employees
- MRNA 5800
- QGEN N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRNA Health Care
- QGEN Health Care
- Exchange
- MRNA Nasdaq
- QGEN Nasdaq
- Market Cap
- MRNA 10.3B
- QGEN 9.1B
- IPO Year
- MRNA 2018
- QGEN 1996
- Fundamental
- Price
- MRNA $25.90
- QGEN $46.76
- Analyst Decision
- MRNA Hold
- QGEN Buy
- Analyst Count
- MRNA 19
- QGEN 7
- Target Price
- MRNA $48.13
- QGEN $49.51
- AVG Volume (30 Days)
- MRNA 10.5M
- QGEN 1.4M
- Earning Date
- MRNA 07-31-2025
- QGEN 07-30-2025
- Dividend Yield
- MRNA N/A
- QGEN 2.83%
- EPS Growth
- MRNA N/A
- QGEN N/A
- EPS
- MRNA N/A
- QGEN 0.42
- Revenue
- MRNA $3,177,000,000.00
- QGEN $2,002,874,000.00
- Revenue This Year
- MRNA N/A
- QGEN $6.36
- Revenue Next Year
- MRNA $9.87
- QGEN $6.18
- P/E Ratio
- MRNA N/A
- QGEN $110.70
- Revenue Growth
- MRNA N/A
- QGEN 3.31
- 52 Week Low
- MRNA $23.15
- QGEN $37.63
- 52 Week High
- MRNA $138.07
- QGEN $47.93
- Technical
- Relative Strength Index (RSI)
- MRNA 46.10
- QGEN 64.44
- Support Level
- MRNA $25.06
- QGEN $46.25
- Resistance Level
- MRNA $28.72
- QGEN $47.70
- Average True Range (ATR)
- MRNA 1.18
- QGEN 0.62
- MACD
- MRNA -0.18
- QGEN -0.00
- Stochastic Oscillator
- MRNA 20.34
- QGEN 68.56
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).